[["index.html", "", "     II (ADME  )  (PIPET), AIMS BioScience, Q-fitter - Ver 0.0.1 (2022-06-03) 2022-09-13  &lt;U+C9C0&gt; /&gt;   ·    (pharmacokinetics)     .               .         ,      .                      .           ,          .              .       (,  )    ,           ,       .                            .       ,                 ,          .    20                    ,    . 1               .                            .      ,      , ,   ,            .                  .      ,                 .   /     ,       .          pdf   . 2  print on demand       /   .                 .      ,                   . 2021 9,      http://pipetlms.or.kr http://pipet.or.kr/books/pharmapk "],["solubility.html", "Chapter 1 (solubility) 1.1  1.2    1.3     1.4  1.5 ", " Chapter 1 (solubility)  1.1  (solubility)             .              (disintegration), (dissolution)  (diffusion)      ( 1.1).  1.1:    (Di and Kerns 2015)      ,      .       ,            . ,          (Ficks law  1). ,              .            .     ,   PK       in vitro assay    in vivo        .  ,    in vitro assay buffer media               .   in vivo               clear solution    PK          .         ,     ,              . 1.2         ?       ?          .     (Permeability),      ,                 .           . Drug discovery           ( 1.1).  1.1: NCA    PK   Solubility (g/mL) Criteria &lt;10 Low 10-60 Moderate &gt;60 High Drug development    USP       .  ,       20±5 5 30     30    ,  1 g  1 mL            ( 1.2).  1.2:   USP      USP   1g  1 mL        Very soluble 1 mL    Freely soluble 1 mL  10 mL   Soluble 10 mL  30 mL    Sparingly soluble 30 mL  100 mL    Slightly soluble 100 mL  1000 mL     Very slightly soluble 1000 mL  10000 mL     Practically soluble 10000 mL         Biopharmaceutics Classification System (BCS)   ( 2).        4 class   . Class I:  ,   Class II:  ,   Class III:  ,   Class IV:  ,   Class I Class III     37  pH 1.2  6.8  1   () 30      250 mL   .   250 mL              .  2. Biopharmaceutics Classification System (BCS) 1.3     1.3.1         .      ,        .           .           .     ,        pKa   pH      .         .  (,     )       (Lipophilicity): LogP  LogD  (Ionizability): pKa 1.3.2            . ,        ,           .          .        .     pH   Compendial media  Bio-relevant media        ( pH  (pH 1.4  8.0),   )     ,     .        ,          .       Compendial media  Bio-relevant media      . 1.3.2.1 Compendial media   pH 1.0  3.0    (pepsin) ,   pH 5.7  7.7    (pancreatin) . Compendial media  pH     .   compendial media USP     ,           ( 3).  compendial media    , , ,           .  3.          (SGF, Stimulated Gastric Fluid)   (SIF, Stimulated Gastric Fluid)  USP       USP       pH 1.2 6.7   Pepsin, HCl, NaCl, water Pancreatin, KH2PO4, NaOH, water 1.3.3 Bio-relevant media Bio-relevant media compendial media   , , ,                 .          4   ( 4). FaSSGF (Fasted state Stimulated Gastric Fluid):        (Bile acid)   (Phospholipid)  . FeSSGF (Fed state Stimulated Gastric Fluid):    .              ,      pH             .          whole milk  Ensure® Plus   . FaSSIF (Fasted state Stimulated Intestinal Fluid):    ,       . FeSSIF (Fed state Stimulated Intestinal Fluid):    .      pH ,            .       mixed micelles    (Solubilization)   .  4. Compendial Media  Bio-relevant Media  Parameters Compendial Media Bio-relevant Media SGF SIF FaSSGF FeSSGF FaSSIF FeSSIF Osmolality (mOsmol/kg) Cannot mimic the GI tracts 120.7 - ~270 ~670 Buffer capacity (mEq/pH/L) - - ~12 ~72 Surface tension (mN/m) 42.6 - 54 48 Ion strength Can mimic the GI tracts Viscosity Food condition Fasted Fasted Fasted Fed Fasted Fed pH 1.2 6.8 1.6 3-6 or neutral 6.5 5.0 Composition Enzyme Pepsin Pancreatin Pepsin Pepsin Pancreatin Pancreatin Bile acid N.A. N.A.     Phospholipid N.A. N.A.     1.3.4          .             .    Kinetic solubility Thermodynamic solubility   . 1.3.4.1 Kinetic solubility Kinetic solubility DMSO      ,  buffer       .             Drug discovery    .   3      stock solution  buffer   in vitro    , Kinetic solubility   in vitro assay      .  3. Kinetic solubility         Nephelometry, Turbidimetry  Direct measurement  ( 5).      ,        ,      Nephelometry.          ,     Turbidimetry.  Direct measurement UV          UV      .  5. Kinetic solubility    Nephelometry Turbidimetry Direct measurement {width=1.7580161854768155 height=2.0277777777777777in} in 1.3.4.2 Thermodynamic solubility Thermodynamic solubility         ,        ( 4).  Thermodynamic solubility Equilibrium solubility .    gold standard   ,  Drug development  .     24         ,      .  4. Kinetic solubility   Thermodynamic solubility            .  Kinetic solubility           ,        ( 5). Thermodynamic solubility Kinetic solubility       ,    (Polymorphism)  (Crystal form) .   Kinetic solubility      (Amorphous form)  .              .  5. Kinetic solubility Thermodynamic solubility  1.4   ADME : Physicochemical properties   .           , in vitro/in vivo            .                 .    highly potent   ,  lipophilicity            .  , , pH buffer, compendial  bio-relevant media          ,     . 1.5  Edward H. Kerns and Li Di, Drug-like properties: Concepts, Structure Design and Methods. Lubrizol Life Science, Biopharmaceutical Classification System, 2019 https://3ehzg6104228bwtte1se19g6-wpengine.netdna-ssl.com/wp-content/uploads/2019/10/TB-28-Biopharmaceutical-Classification-System.pdf Everything you need to know about ADME, 3rd Edition, Cyprotex Alskär, L. C. et al., Improved molecular understanding of lipid-based formulations, Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 262, 2018. Eleni Rinaki et al., Pharmaceutical Research, 20(12), 2003. Sandra Klein et al., The AAPS Journal, 12(3), 2010. Mark G. Papich and Marilyn N. Martinez, The AAPS Journal, 2015. Edward H. Kerns et al., Current Drug Metabolism, 9, 879-885, 2008. M9 Biopharmaceutics classification system based biowaivers, 2018. Jochen Maas et al., European Journal of Pharmaceutics and Biopharmaceutics, 66, 1-10, 2007. Prachi Shekhawat and Varsha Pokharkar, Acta Pharmaceutica Sinica B, 2016.  "],["permeability.html", "Chapter 2 Permeability", " Chapter 2 Permeability  2.1   (Permeability)      .     ,            . , ,                ,       .   , , ,               ( 2.1).  2.1.              ,                       . 2.2   2.2.1         (phospholipid bilayer)  ,     ,          ( 2.2).  2.2.  :                 .    brush border    ,       (basolateral membrane)   .  transcellular        (passive transport)    (carrier), ,           (active transport)   .    (tight junction)  paracellular     ( 2.3).       ,       .               ,            .  2.3.    2.2.2                   .           ,   pKa    pH      .  soluble           .        ,    uptake  efflux transporter        (affinity)      ( 2.4).        . High lipophilicity Low ionizability High solubility High affinity to the uptake transporters Low affinity to the efflux transporters  2.4.      2.3    2.3.1 PAMPA (Parallel Artificial Membrane Permeability Assay)   ,           .              ,             PAMPA    . PAMPA   2.5    Kit  . , ()       2.5. PAMPA    DMSO      stock solution .  Donor plate well      PBS buffer    , Acceptor plate well PBS buffer  25 C 5    Donor  Acceptor plate   LC-MS/MS        Pe . \\[P_{e} = C\\ \\times \\left\\lbrack - Ln\\mspace{6mu}\\left( 1 - \\frac{\\lbrack drug\\rbrack_{acceptor}}{\\lbrack drug\\rbrack_{equilibrium}} \\right) \\right\\rbrack\\] \\[drug\\]equilibrium = \\[drug\\]donor *VD + \\[drug\\]acceptor x VA / (VD + VA) C = VD × VA / \\[(V~D~ + V~A~) × t × A\\] VD = volume of donor compartment VA = volume of acceptor compartment A = filter area t = incubation time (in seconds) \\[drug\\]acceptor = Concentration of compound in the acceptor compartment at the assay completion \\[drug\\]donor = Concentration of compound in the donor compartment at the assay completion \\[drug\\]equilibrium = Concentration of compound at theoretical equilibrium      ,   UV plate reader           PAMPA      .     (cell-based assay)     pH   ,       .   PAMPA-BBB  Brain-Blood Barrier      . ,  UV plate reader         ,           .                transporter        . 2.3.2 Caco-2 cell-based permeability assay     Caco-2   , Caco-2           (: microvilli  tight junction )         . Caco-2    2.6   , well plate monolayer Caco-2  , Apical  Basolateral side          Apical  Basolateral side    .  2.6. Caco-2 cell-based permeability assay          (Papp, Apparent permeability coefficient)  Efflux ratio . Papp= (dQ/dt) / (AC0) Efflux ratio = Papp (B to A)/ Papp (A to B)  dQ/dt     (initial transport rate, mol/s), A well  (the surface area of the monolayer, cm2), C0    (initial concentration in the donor chamber, mol/cm3) . Caco-2             ,  (Apical membrane)   (Basolateral membrane)     .         P-glycoprotein (P-gp)  Breast cancer resistant protein (BCRP)  efflux transporter      (  Efflux ratio &gt; 2).     3  ,  1  antibiotics-free media    contamination                 .  Caco-2              . 2.3.3 MDCK cell-based permeability assay    MDCK (Madin-Darby Canine Kidney)   ,   tight junction   cell monolayer   . Caco-2      , efflux transporter     .  Caco-2    ,  3~4  cell monolayer       .   transporter     transporter      (transfected cell line)   .        transporter          (: MDCK II-MDR1 cell line).  2.7. MDCK cell-based permeability assay  2.1.        PAMPA Caco-2 cell-based MDCK cell-based Cell origin Artificial membrane Human colorectal carcinoma cells Madin-Darby canine kidney strain cells Cell morphology - Intestinal epithelium Distal tubule epithelium Cell growing time - &gt; 21 days 3~4 days Permeation mechanisms Passive diffusion Passive diffusion, Active transport, Paracellular and Efflux Direction of transport One-way (Donor  Acceptor) B i-directional (Apical  Basolateral) Expression of transporters Uptake transporters Not expressed OATP1B1, OATP1B3, OATP2B1, PepT1, OCT1, OCT2 and OCT3 OCT2, peptide and m onocarboxylic acids Efflux transporters Not expressed P-gp (MDR1), MRP2, MRP4 and BCRP P-gp (MDR1), MRP1, MRP2 and MRP5 Metabolism No Yes Yes -: not applicable. 2.4         in vitro         ,         .  in vitro                .        (drug discovery)      .  Caco-2                ( 2.8). FDA   (Biopharmaceutics Classification System, BCS) 6 ,                    Caco-2         .  Caco-2       (absorption rate constant, ka)     .  2.8. Caco-2        PAMPA             .     , PAMPA     (Pe) 10*10-6 cm/sec       .  Pe  10*10-6 cm/sec         , 1*10-6 cm/sec          . Caco-2   Apical to Basolateral    (Papp, A to B)       (reference drug)           .      FDA    ,     (fraction of human intestinal absorption; fa)  high (85%), moderate (50 - 84%), low (&lt;50%)  zero-permeable   .         high  low-permeable   1      .   ,      efflux ratio 2       efflux transporter   .   efflux transporter  ,   transporter               .   2.2  , P-gp     P-gp  Talinolol  Verapamil      .    Test drug A  P-gp  Talinolol   .  efflux ratio 2   Verapamil    apical to basolateral  Papp  2      .      efflux ratio 44.4    2  .  Test drug A P-gp   .  Test drug B efflux ratio  2 ,     Papp  efflux ratio     .  Test drug B P-gp  , P-gp  Caco-2    efflux transporter    .  2.2. Caco-2   P-gp    C ompound Without Ve rapamil (P-gp inhib itor) With Ve rapamil (P-gp inhib itor) *Papp (A to B)** \\[ x10^-6^ c m/sec\\] *Papp (B to A)** \\[ x10^-6^ c m/sec\\] Efflux r atio *Papp (A to B)** \\[ x10^-6^ c m/sec\\] *Papp (B to A)** \\[ x10^-6^ c m/sec\\] Efflux r atio Ta linolol (P-gp sub strate) 0.292 11.5 39.3 1.07 1.34 1.25 Test drug A [0.397] {.under line} 40.1 [ 101]{. underl ine} [0.959] {.under line} 42.6 [4 4.4]{. underl ine} Test drug B 12.6 22.5 1.78 11.8 24.3 2.05 Papp (A to B): permeability coefficient in apical to basolateral direction, Papp (B to A): permeability coefficient in basolateral to apical direction. 2.5            ,                  . \\[\\mathbf{Recovery\\ }\\left( \\mathbf{\\%} \\right) = \\frac{total\\ compound\\ in\\ both\\ of\\ A/B\\ sides\\ at\\ the\\ end\\ of\\ experiment\\ (nmol)}{initial\\ compound\\ present\\ (nmol)}\\ \\times \\ 100\\] A: apical, B: basolateral.            low-permeable      ,                     .   75%             ,         . Non-specific binding of test compound to plastic material Poor solubility of test compound in the media Instability of test compound in the media (i.e., due to the metabolism in cell) Accumulation of test compound in the cell monolayer        plastic ware   (non-specific binding)    bovine serum   plastic  bovine serum       plastic material     wash out         . 2.6   ADME : physicochemical properties   .        ,            .       efflux transporter      .        in vitro  ,       ,        .          ,      .   .     I (2021). .  :  3 (2005). Di, Li, and Edward Kerns. Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization. Academic press (2015). Cyprotex Ltd. Everything you need to know about ADME, 3rd Edition (2017). Volpe, Donna A. \"Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.\" Future medicinal chemistry 3.16 (2011): 2063-2077. ICH Harmonised Guideline, M9 Biopharmaceutics Classification System-Based Biowaivers (2018). Saxena, Amrita, et al. \"Pharmacokinetics, dose proportionality and permeability of S002-333 and its enantiomers, a potent antithrombotic agent, in rabbits.\" Xenobiotica 45.11 (2015): 1016-1023. Masungi, C., et al. \"Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates.\" Die Pharmazie-An International Journal of Pharmaceutical Sciences 63.3 (2008): 194-199. "],["plasma-protein-binding.html", "Chapter 3 Plasma protein binding 3.1  3.2       3.3     3.4      3.5     3.6 ", " Chapter 3 Plasma protein binding  3.1             ,           .                  ,           .              ,    (free drug hypothesis)  ( 3.1).  3.1:           ,       ,       .   plasma, tissue  microsome      ,                . 3.2              albumin, 1-acid-glycoprotein (AGP), lipoprotein  globulin  .   albumin       50%   ,          .  albumin   8  ,   2       .  AGP, lipoprotein     ,    AGP , lipoprotein ,      , globulin ,     . 3.3             (fluorescence spectroscopy),     (Chromatography and capillary electrophoresis), (Microdialysis),  (Equilibrium Dialysis),  (Ultrafiltration)    (Ultracentrifugation)     .      ,     ,         . 3.3.1  (Equilibrium Dialysis)  (Equilibrium Dialysis)      gold standard  .   3.2         RED (Rapid Equilibrium Dialysis) device     . Plasma chamber (Red)    , Buffer chamber (White) phosphate buffer         ( 4-24) 37  .   Plasma chamber        ,       Buffer chamber    .     Plasma  Buffer chamber     3.1  ,  (fraction bound, fb)    (fraction unbound, fu)   .  3.2  (Equilibrium Dialysis) \\(\\% Bound = \\frac{Conc.of\\ \\mathbf{buffer}\\ chamber}{Conc.of\\ \\mathbf{sample}\\ chamber} \\times 100(\\%)\\), %\\(Unbound = 100 - \\% Bound,{\\ \\ \\ \\mathbf{f}}_{\\mathbf{u}} = \\ \\frac{\\%_{\\mathbf{unbound}}}{\\mathbf{100}}\\) ( 3.1)    Plasma Buffer chamber   ,                 .            .  4 ,  24    ,        (recovery)   , Plasma  Buffer chamber     volume    . 3.3.2  (ultrafiltration)   (ultrafiltration)            ,  Buffer                (filtrate)     .   3.3                        .             .      ,         3.2  ,   (non-specific binding, NSB)    (fraction unbound, fu)   . , , ()       3.3  (ultrafiltration)  , ( 3.2)          ,       .        ,         . 3.3.3  (Ultracentrifugation)   (Ultracentrifugation)   tube   ,    (: 500,000 g, 10-24 )      aqueous layer       ( 3.4).             ,    upper layer ()       aqueous layer      .           ,          .  3.4  (Ultracentrifugation)  3.4              .       ,        .   90%    ,  highly potent       lipophilicity ,   90%     .   ,  98% high, 90-98% moderate  90%  low       .           .          ,                   .   ,           .    99.9% (fraction bound, fb = 0.999)      99.8% ,  0.1%     ,    (fraction unbound, fu) 0.01 0.02 2         .  (Therapeutic index)               .  , ,     .  ,             (free drug concentration) time profile in vitro   IC50  EC50        , in vitro hERG assay  IC50        .  FDA           R value    .  human PK prediction       IVIVE (In Vitro-In Vivo Extrapolation)  . 3.5     3.5.1   (Low recovery)   ,     .                ,   plastic ware        (non-specific binding, NSB) .                  .                 ,                 .   ,           ( 3.1).       lead optimization  ,       ,     ,         .  3.1     ()      3.5.2           100   98% (Smith, Dennis A, 2010), FDA  189      99%              ( 3.5).  3.5 US FDA  189   (Xingrong Liu, 2014)       Buffer chamber     , Buffer chamber             .          .      RED device   ,              .   3.3  10        . \\(\\% Bound = \\frac{Conc.of\\ \\mathbf{buffer}\\ chamber}{Conc.of\\ \\mathbf{sample}\\ chamber} \\times 100(\\%)\\), %\\(Unbound = 100 - \\% Bound\\) \\({\\ \\ \\ f}_{u\\ 10\\%} = \\ \\frac{\\%_{unbound}}{100}\\ \\ ,\\ \\ \\ \\ \\ \\ \\ {\\ \\ \\ f}_{u\\ 100\\%} = \\ \\frac{{\\ \\ \\ f}_{u\\ 10\\%}}{10\\ - 9*f_{u\\ 10\\%}}\\ \\ \\ \\ \\ \\ \\ \\ \\)( 3.3)              (TRANSIL High Sensitivity Binding Kit3)  ,           . 3.6   ADME : Physicochemical properties         .              .   , , ,  PK       ,    . ,       .  \\[1\\] Tonika; Gan, Liang-Shang. Plasma protein binding: From discovery to development. Journal of Pharmaceutical Sciences, 102(9), 29532994, 2013. \\[2\\] Van Liempd, Sebastiaan; Morrison, Denise; Sysmans, Leen; Nelis, Paul; Mortishire-Smith, Russell. Development and Validation of a Higher-Throughput Equilibrium Dialysis Assay for Plasma Protein Binding. Journal of Laboratory Automation, 16(1), 5667, 2011. \\[3\\] Li Di; John P. Umland; Patrick E. Trapa; Tristan S. Maurer. Impact of recovery on fraction unbound using equilibrium dialysis. 101(3), 13271335, 2012. \\[4\\] Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A. Rational Use of Plasma Protein and Tissue Binding Data in Drug Design. Journal of Medicinal Chemistry, 57(20), 82388248, 2014. \\[5\\] Buscher, Brigitte; Laakso, Sirpa; Mascher, Hermann; Pusecker, Klaus; Doig, Mira; Dillen, Lieve; Wagner-Redeker, Winfried; Pfeifer, Thomas; Delrat, Pascal; Timmerman, Philip. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum. Bioanalysis, 6(5), 673682, 2014. \\[6\\] Edward H. Kerns and Li Di, Drug-like properties: Concepts, Structure Design and Methods. \\[7\\] Everything you need to know about ADME, 3rd Edition, Cyprotex https://sovicell.com/products/tpb-0400-0135 "],["translation.html", "Chapter 4 Translation 4.1  4.2 (F)  4.3    4.4 Vd  4.5 CL  4.6    translation 4.7    ", " Chapter 4 Translation 4.1  In vitro, in vivo   PK, PD    translation              . In vitro ADME            .                 CL, Vd, ka, F       .            , in vitro ADME          . In vitro                         .   3    in vivo PK  allometry   PK        in vitro    in vivo           .       PK                . In vitro ADME        -  (drug-drug interaction, DDI)  .        ,         PK  ,           in vitro    PBPK    .         DDI              .     (tutorial) n               .  Transl Clin Pharmacol. 2020 Sep;28(3):126-135 https://doi.org/10.12793/tcp.2020.28.e14  Transl Clin Pharmacol. 2020 Dec;28(4):169-174 https://doi.org/10.12793/tcp.2020.28.e19  Transl Clin Pharmacol. 2021 Jun;29(2):78-87 https://doi.org/10.12793/tcp.2021.29.e12    PK            .  in vitro, in vivo      PK                      1         . ,     PK          . 4.2 (F)  F F = Fa · Fg · Fh     . Fh CLh       . 4.2.1 Fa  Fa             .     ,  (pKa)   . Caco-2 (permeability)   Fa     . Fa              . Fa    human jejunal permeability ,            Caco-2    .     Caco-2     human jejunal permeability     Fa  Fa  . ( 4.1) (Sun et al. 2002)      4.1)            Fa          .  Caco-2            .    Caco-2   ,                    . Caco-2                   .           Caco-2         Fa        .  4.1: Caco-2  human jejunal permeability, Fa    (Sun et al. 2002)   polar surface area (PSA) Fa                     PSA Fa          (unpublished data)     . 4.2.2 Fg              .    CYP450  80% 3A4       CLint in vitro    CYP3A4    CYP3A4      .    CLint      CLint    . (     ?) 4.2.3 Fh  Fh   CLh   .  Well-stirred model           . &lt;   chapter   . &gt; 4.3         F         .    1       ka  .    ka     Usansky    Caco-2 , , Vc  . (Usansky and Sinko 2005)         Cmax   Cmax     AUC   1          Cmax     .         Cmax     2    Cmax              1  Cmax           . 1                .          1 ,                         1       .  1                .         1          Cmax             2     .  PK             .               PK                         .          Cmax   (AUC)              .       pH  CYP      PBPK           . 4.4 Vd  4.4.1 PBPK         .   /,               .    (ktp)       ,                fu   Vdss .    fu       fu     . (Yim and Choi 2020)  PBPK  Vdss    ,       Vc, Vp    . 4.4.2 Allometry    allometry 3       2    Vc, Vp, Q (intercompartmental CL)        . Allometry  Vd CL     , CL         .   Vd   allometry  ,     2     , Vd            allometry      .          Vd  PBPK allometry                         .   in vitro   PK      allometry   . 4.5 CL       CL  in vivo     .       CYP          in vitro ,      CYP   in vitro   .       CL .       (Transl Clin Pharmacol. 2021 Jun;29(2):78-87 https://doi.org/10.12793/tcp.2021.29.e12)      .      (QHB),  (fuB) intrinsic CL (CLu,int,H)  Well-stirred model   . \\[{CL}_{H}(L/h) = \\frac{Q_{HB} \\bullet f_{uB} \\bullet {CL}_{u,int,H}}{Q_{HB} + f_{uB} \\bullet {CL}_{u,int,H}}\\]    CLu,int,H    (  1)   CLu,int   (1200 )  .  1 CLu,int     (, microsome,  CYP)    ,        ,         .      ADME         raw data         . 4.6    translation in vitro       -    ,              in vitro    .     in vitro                     .           ,      in vtiro     ( rifampin) ( itraconazole)     ,    in vitro  PBPK       .         (rifampin itraconazole )   PBPK       AUC, Cmax    PBPK         . 4.7        in vitro        fu          .              99.9%    (, fu 0.1% ) FDA     fu 0.1%   .  in vitro                 fu = 1    .    free drug hypothesis    (Cu,ss) in vitro     IC50, Km, EC50         .           discovery            .     .    30~40% fu 0.1, 0.01  5~10%   (ref: Current Topics in Medicinal Chemistry 2011; 11:450-466). 65          Cu,ss   in vitro  (IC50, Km, EC50) (ratio)       Cu,ss IC50    69% . (Korean J Physiol Pharmacol 2019;23(4):231-236)  4.2: In vitro  potency(IC50, EC50 )      Cu,ss . (Yim 2019)           statin      (PPIs)           . , in vitro   in vivo          ,   in vitro      .           , in vitro          PK     . * bookdown        .  "],["-1.html", "", "  "],["404.html", "Page not found", " Page not found The page you requested cannot be found (perhaps it was moved or renamed). You may want to try searching to find the page's new location, or use the table of contents to find the page you are looking for. "]]
